172 related articles for article (PubMed ID: 15265845)
1. HER-2 and fluorescent in situ hybridization to evaluate breast cancer.
Tanvetyanon T
JAMA; 2004 Jul; 292(3):328; author reply 328-9. PubMed ID: 15265845
[No Abstract] [Full Text] [Related]
2. HER-2 testing in breast cancer using parallel tissue-based methods.
Yaziji H; Goldstein LC; Barry TS; Werling R; Hwang H; Ellis GK; Gralow JR; Livingston RB; Gown AM
JAMA; 2004 Apr; 291(16):1972-7. PubMed ID: 15113815
[TBL] [Abstract][Full Text] [Related]
3. HER2 status and benefit from adjuvant trastuzumab in breast cancer.
Paik S; Kim C; Wolmark N
N Engl J Med; 2008 Mar; 358(13):1409-11. PubMed ID: 18367751
[No Abstract] [Full Text] [Related]
4. Counterpoint: Both immunohistochemistry and fluorescence in situ hybridization play important roles for HER2 evaluation.
Bloom KJ; Cote RJ
Clin Chem; 2011 Jul; 57(7):983-5. PubMed ID: 21558454
[No Abstract] [Full Text] [Related]
5. New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody.
Sakamoto G; Mitsuyama S
Breast Cancer; 2000; 7(4):350-7. PubMed ID: 11114864
[No Abstract] [Full Text] [Related]
6. HER2 testing and correlation with efficacy of trastuzumab therapy.
Konecny G; Slamon DJ
Oncology (Williston Park); 2002 Nov; 16(11):1576, 1578. PubMed ID: 12469932
[No Abstract] [Full Text] [Related]
7. Saving lives with accurate HER2 testing.
Ross JS
Am J Clin Pathol; 2010 Aug; 134(2):183-4. PubMed ID: 20660318
[No Abstract] [Full Text] [Related]
8. HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese M; Zimmern RL; Pinder SE
J R Soc Med; 2007 Jul; 100(7):326-9. PubMed ID: 17606754
[TBL] [Abstract][Full Text] [Related]
9. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy.
Chorn N
Oncol Nurs Forum; 2006 Nov; 33(2):265-72. PubMed ID: 16518442
[TBL] [Abstract][Full Text] [Related]
10. A comparison of HER2/neu gene amplification and its protein overexpression between primary breast cancer and metastatic lymph nodes.
Aoyama K; Kamio T; Nishikawa T; Kameoka S
Jpn J Clin Oncol; 2010 Jul; 40(7):613-9. PubMed ID: 20202990
[TBL] [Abstract][Full Text] [Related]
11. [HER-2 diagnostics].
Bánkfalvi A
Magy Onkol; 2002; 46(1):11-5. PubMed ID: 12050677
[TBL] [Abstract][Full Text] [Related]
12. Point: Fluorescence in situ hybridization is the preferred approach over immunohistochemistry for determining HER2 status.
Ross JS
Clin Chem; 2011 Jul; 57(7):980-2. PubMed ID: 21558455
[No Abstract] [Full Text] [Related]
13. Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
Lipton A; Köstler WJ; Leitzel K; Ali SM; Sperinde J; Weidler J; Paquet A; Sherwood T; Huang W; Bates M;
Cancer; 2010 Nov; 116(22):5168-78. PubMed ID: 20661914
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of HER2 status in breast cancer].
Penault-Llorca F; Cayre A
Bull Cancer; 2004 Dec; 91 Suppl 4():S211-5. PubMed ID: 15899610
[TBL] [Abstract][Full Text] [Related]
15. The use of HER2 testing in the management of breast cancer.
Ravdin P
Semin Oncol; 2000 Oct; 27(5 Suppl 9):33-42. PubMed ID: 11049055
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab in the treatment of breast cancer.
Hortobagyi GN
N Engl J Med; 2005 Oct; 353(16):1734-6. PubMed ID: 16236745
[No Abstract] [Full Text] [Related]
17. [Indications for treatment in invasive ductal carcinoma of the breast with Herceptin from the aspect of laboratory diagnosis--study of the ERBB-2 protein and determination of the number of copies of the ERBB2 gene. Review].
Mrhalová M; Kodet R
Cesk Patol; 2002; 38 Suppl 1():4-14. PubMed ID: 12677891
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 testing recommendation.
Raji A; Lurie RH
Arch Pathol Lab Med; 2007 Sep; 131(9):1330-1; author reply 1331-3. PubMed ID: 17824785
[No Abstract] [Full Text] [Related]
19. [HER2 testing in breast cancer].
Yoshimura K
Nihon Rinsho; 2007 Jun; 65 Suppl 6():275-80. PubMed ID: 17682167
[No Abstract] [Full Text] [Related]
20. Addition of trastuzumab to chemotherapy produces 50% increase in survival in patients selected by FISH.
Oncology (Williston Park); 2001 Oct; 15(10):1345, 1364. PubMed ID: 11702961
[No Abstract] [Full Text] [Related]
[Next] [New Search]
